|Day Low/High||6.81 / 7.11|
|52 Wk Low/High||6.01 / 18.22|
Stemline Therapeutics, Entercom Communications and Ocular Therapeutix offer reasons to think their shares will perform better in the New Year.
Shares of Stemline Therapeutics and Entercom Communications headed opposite directions last Friday after reporting results.
Stemline Therapeutics and Entercom Communications seem to have stabilized after notable declines late in the summer.
Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
"The true New Yorker secretly believes that people living anywhere else have to be, in some sense, kidding." - John Updike The market is little changed from our noon update. It has been a lackluster day of trading in front of the Fed meeting. Not do...
A trial patient died from a Stemline Therapeutics' SL-401 cancer drug side effect, the family confirmed.
Gladstone Land, KaloBios Pharmaceuticals and Stemline Therapeutics plan to go public, IPO Desktop President Francis Gaskins isn't sure the risk is worth it.
IPO Desktop President Francis Gaskins likes Globus Medical, but is content to wait for Stemline.